Tocilizumab: From Rheumatic Diseases to COVID-19
- PMID: 33719967
- DOI: 10.2174/1381612827666210311141512
Tocilizumab: From Rheumatic Diseases to COVID-19
Abstract
Tocilizumab is a humanised interleukin-6 receptor-inhibiting monoclonal antibody that is currently approved for the treatment of rheumatoid arthritis and other immune-related conditions. Recently, tocilizumab has been investigated as a possible treatment for severe coronavirus-induced disease 2019 (COVID-19). Despite the lack of direct antiviral effects, tocilizumab could reduce the immune-induced organ damage caused by severe acute respiratory syndrome-coronavirus 2 (SARS-CoV2) infection. Until recently, most reports on tocilizumab for COVID-19 included a limited number of patients, preventing an overall evaluation of its efficacy and safety for this specific condition. Therefore, we reviewed the literature regarding the physiopathological rationale of tocilizumab for COVID-19 and its outcomes. We searched the MEDLINE database with the string "(SARS-CoV-2 OR coronavirus OR COVID-19 OR MERS- cov OR SARS-cov) AND (IL-6 OR interleukin 6 OR tocilizumab)". While the scientific rationale supporting tocilizumab for COVID-19 is solid, the evidence regarding the outcomes remains controversial. Available data and results from ongoing trials will provide useful information in the event of new COVID-19 outbreaks or future pandemics from different coronaviruses.
Keywords: COVID-19; SARS-CoV2; Tocilizumab; cytokines.; interleukin-6; monoclonal antibodies; tocilizumab.
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
Similar articles
-
Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy.J Autoimmun. 2020 May;109:102442. doi: 10.1016/j.jaut.2020.102442. Epub 2020 Apr 2. J Autoimmun. 2020. PMID: 32253068 Free PMC article. Review.
-
Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review.Rev Recent Clin Trials. 2021;16(2):138-145. doi: 10.2174/1574887115666200917110954. Rev Recent Clin Trials. 2021. PMID: 32940187 Review.
-
Therapeutic Role of Tocilizumab in SARS-CoV-2-Induced Cytokine Storm: Rationale and Current Evidence.Int J Mol Sci. 2021 Mar 17;22(6):3059. doi: 10.3390/ijms22063059. Int J Mol Sci. 2021. PMID: 33802761 Free PMC article. Review.
-
Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review.Pulmonology. 2021 Jan-Feb;27(1):52-66. doi: 10.1016/j.pulmoe.2020.07.003. Epub 2020 Jul 20. Pulmonology. 2021. PMID: 32713784 Free PMC article.
-
Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.Trials. 2020 Jun 3;21(1):468. doi: 10.1186/s13063-020-04453-5. Trials. 2020. PMID: 32493441 Free PMC article.
Cited by
-
LZM008, a proposed tocilizumab biosimilar: Pharmacokinetics, safety, and immunogenicity profiles compared with ACTEMRA® in Chinese healthy male subjects.Front Pharmacol. 2023 Apr 4;14:1111893. doi: 10.3389/fphar.2023.1111893. eCollection 2023. Front Pharmacol. 2023. PMID: 37081963 Free PMC article.
-
Lessons learnt from broad-spectrum coronavirus antiviral drug discovery.Expert Opin Drug Discov. 2024 Sep;19(9):1023-1041. doi: 10.1080/17460441.2024.2385598. Epub 2024 Jul 30. Expert Opin Drug Discov. 2024. PMID: 39078037 Review.
-
The impact of ivermectin on COVID-19 outcomes: a systematic review and meta-analysis.Ann Med Surg (Lond). 2025 Jan 7;87(2):809-829. doi: 10.1097/MS9.0000000000002762. eCollection 2025 Feb. Ann Med Surg (Lond). 2025. PMID: 40110299 Free PMC article.
-
Nanotechnology-Driven Strategy Against SARS-CoV-2: Pluronic F127-Based Nanomicelles with or Without Atazanavir Reduce Viral Replication in Calu-3 Cells.Viruses. 2025 Apr 1;17(4):518. doi: 10.3390/v17040518. Viruses. 2025. PMID: 40284961 Free PMC article.
-
Evaluation of the efficacy and safety of nirmatrelvir/ritonavir co-administration inpatients with rheumatic disease infected with SARS-CoV-2: a real-world study.Front Pharmacol. 2023 Dec 6;14:1288402. doi: 10.3389/fphar.2023.1288402. eCollection 2023. Front Pharmacol. 2023. PMID: 38125894 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous